Imunon’s (IMNN) Buy Rating Reiterated at HC Wainwright

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock.

Other equities analysts also recently issued reports about the company. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research report on Monday, September 23rd. D. Boral Capital restated a “buy” rating and issued a $29.00 price target on shares of Imunon in a research report on Thursday.

Imunon Stock Performance

Shares of NASDAQ:IMNN traded up $0.00 during mid-day trading on Thursday, reaching $0.83. 385,123 shares of the company’s stock were exchanged, compared to its average volume of 896,589. The firm has a market capitalization of $12.05 million, a price-to-earnings ratio of -0.44 and a beta of 2.12. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65. The business’s fifty day moving average price is $0.88 and its 200-day moving average price is $1.08.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.